Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γ Agonist against MPTP
Figure 1
LSN862 (LSN) conferred neuroprotection against MPTP nigrostriatal loss in a dose-dependent manner. Mice brains were evaluated 21 days after completing MPTP or PBS challenge and 24 hrs after daily treatment with LSN doses or vehicle. Quantifications were performed in the following groups: vehicle + PBS (); vehicle + MPTP (); 3 mg/kg LSN + PBS (); 3 mg/kg LSN + MPTP (); 10 mg/kg LSN + PBS (); 10 mg/kg LSN + MPTP (); 30 mg/kg LSN + PBS (); and 30 mg/kg LSN + MPTP (). (a) Coronal images at the level of striatum (ST) and substantia nigra (SN) immunostained for tyrosine hydroxylase (TH). Scale bar: ST = 1 mm, SN = 200 μm. (b) TH optical density (OD) of striatal fibers (mean ± SEM). Independent -test # (vehicle + PBS versus vehicle + MPTP), * (vehicle + MPTP versus 30 mg/kg LSN + MPTP). (c) Stereological cell quantification of TH positive nigral neurons (mean ± SEM; per group) ANOVA (Fisher’s LSD post hoc) # (vehicle + PBS versus vehicle + MPTP), * (vehicle + MPTP versus 30 mg/kg LSN + MPTP).
